Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

After hours: February 19 at 5:48:58 PM EST Loading Chart for DIN ...